Products
Not All PDE4 Inhibitors Are the Same
Phosphodiesterase 4 (PDE4) has been implicated in a wide range of inflammatory diseases, and is an established target in dermatology. However, not all PDE4 inhibitors are the same. Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer at Arcutis, discusses the unique properties of topical roflumilast (ZORYVE®).
Indications
ZORYVE (roflumilast) cream, 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.
ZORYVE (roflumilast) foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
The most common adverse reactions (≥1%) for ZORYVE topical foam 0.3% include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.
For more information,
visit the ZORYVE website.
US-CRP-151-00017
